Catalent (CTLT)
(Delayed Data from NYSE)
$56.03 USD
-0.02 (-0.04%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $56.00 -0.03 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTLT 56.03 -0.02(-0.04%)
Will CTLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CTLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTLT
Charles River (CRL) Forges Collaboration With Ship of Theseus
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
CTLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for CTLT
Goldman’s debt issuers stocks basket
Laughing Water Capital Q1 2024 Letter
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC